logo
Plus   Neg
Share
Email

Freeport-McMoRan Reports Agreements For Inalum's Acquisition Of Shares In PT-FI

Freeport-McMoRan Inc. (FCX) announced it has entered into a divestment agreement on previously agreed economic terms with the Indonesian state-owned enterprise PT Indonesia Asahan Aluminium (Persero) (Inalum) in connection with Inalum's acquisition of shares of PT Freeport Indonesia. Inalum will acquire for cash consideration of $3.85 billion all of Rio Tinto's interests associated with its Joint Venture with PT Freeport Indonesia (Joint Venture), and 100 percent of FCX's interests in PT Indocopper Investama, which owns 9.36 percent of PT Freeport Indonesia.

At closing, Rio Tinto will receive $3.5 billion, and Freeport-McMoRan will receive $350 million, in cash proceeds. Under the terms of the divestment agreement, the Rio Tinto interests will be merged into PT Freeport Indonesia concurrent with Inalum's acquisition in exchange for a 40 percent share ownership in PT Freeport Indonesia.

Following completion of the transactions, PT Freeport Indonesia will have an expanded asset base to include the Rio Tinto interests and Inalum's share ownership will be 51.2 percent of PT Freeport Indonesia, and Freeport-McMoRan's ownership will be 48.8 percent.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
MillerCoors LLC has filed a lawsuit against Anheuser-Busch Companies LLC, part of Anheuser-Busch InBev, alleging that Anheuser-Busch's ad campaigns associating MillerCoors' products, Miller Lite and Coor Light, with corn syrup is "false and misleading." During the Super Bowl, ABInBev ran an advertising campaign that mocked Miller Lite and Coors Light use corn syrup in brewing. Shares of Biogen Inc. are falling almost 28 percent in Thursday's trading after the company and Japanese drugmaker Eisai Co. said they will discontinue two late-stage trials for their experimental Alzheimer's drug, Aducanumab. The two Phase 3 trials, ENGAGE and EMERGE, are multi-center, randomized, double-blind, placebo-controlled, parallel-group studies designed to evaluate Aducanumab. The European Union on Wednesday ordered Alphabet Inc.'s Google to pay an antitrust fine of 1.49 billion euros for abusing its dominant position in the online search advertising intermediation market by preventing competition. This is the third antitrust fine by the EU against Google and it represents 1.29 percent of the tech giant's turnover in 2018.
Follow RTT